Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.
Company profile
Ticker
ZTS
Exchange
Website
CEO
Kristin Peck
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Abaxis Europe GmbH • Abaxis, Inc. • Adivo GmbH • Alpharma (Bermuda), LLC • Alpharma (Luxembourg) S.A.R.L. • Alpharma Animal Health (Hong Kong) Co. Limited • Alpharma Animal Health Company • Alpharma Euro Holdings, LLC • Alpharma Holdings (Barbados) SRL • Alpharma, LLC ...
IRS number
460696167
ZTS stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
16 Apr 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors
1 Apr 24
PRE 14A
Preliminary proxy
27 Mar 24
10-K
2023 FY
Annual report
13 Feb 24
8-K
Zoetis Reports Fourth Quarter and Full Year 2023 Results
13 Feb 24
8-K
Zoetis Declares Second Quarter 2024 Dividend
6 Feb 24
8-K
Zoetis Declares First Quarter 2024 Dividend; Board Approves 15% Payment Increase
7 Dec 23
Transcripts
ZTS
Earnings call transcript
2023 Q4
13 Feb 24
ZTS
Earnings call transcript
2023 Q3
2 Nov 23
ZTS
Earnings call transcript
2023 Q2
8 Aug 23
ZTS
Earnings call transcript
2023 Q1
4 May 23
ZTS
Earnings call transcript
2022 Q4
14 Feb 23
ZTS
Earnings call transcript
2022 Q3
3 Nov 22
ZTS
Earnings call transcript
2022 Q2
4 Aug 22
ZTS
Earnings call transcript
2022 Q1
5 May 22
ZTS
Earnings call transcript
2021 Q4
15 Feb 22
ZTS
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.75 bn | 1.75 bn | 1.75 bn | 1.75 bn | 1.75 bn | 1.75 bn |
Cash burn (monthly) | (no burn) | 62.75 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 429.52 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 1.32 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 21.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
62.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1390 |
Opened positions | 176 |
Closed positions | 340 |
Increased positions | 525 |
Reduced positions | 498 |
13F shares | Current |
---|---|
Total value | 50.30 tn |
Total shares | 285.95 mm |
Total puts | 225.33 k |
Total calls | 52.90 k |
Total put/call ratio | 4.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 40.33 mm | $7.96 tn |
STT State Street | 19.32 mm | $3.81 tn |
Capital International Investors | 14.68 mm | $2.90 tn |
T. Rowe Price | 13.72 mm | $2.71 bn |
MS Morgan Stanley | 12.32 mm | $2.43 tn |
Capital World Investors | 9.06 mm | $1.79 tn |
Wellington Management | 9.02 mm | $1.78 tn |
FMR | 7.92 mm | $1.56 tn |
NTRS Northern Trust | 5.93 mm | $1.17 tn |
Polen Capital Management | 4.97 mm | $981.27 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Lagano Roxanne | Common Stock | Sell | Dispose S | No | Yes | 151.17 | 923 | 139.53 k | 14,800 |
5 Apr 24 | Soria Ester Banque | Phantom Stock Unit Common Stock | Grant | Acquire A | No | No | 53.31 | 25.252 | 1.35 k | 25.252 |
5 Apr 24 | Robert J Polzer | Phantom Stock Unit Common Stock | Grant | Acquire A | No | No | 53.31 | 344.798 | 18.38 k | 8,821.862 |
5 Apr 24 | Peck Kristin C | Phantom Stock Unit Common Stock | Grant | Acquire A | No | No | 53.31 | 1,976.322 | 105.36 k | 50,883.925 |
5 Apr 24 | Heidi C. Chen | Phantom Stock Unit Common Stock | Grant | Acquire A | No | No | 53.31 | 318.289 | 16.97 k | 9,695.779 |
News
Zoetis Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
23 Apr 24
Barclays Maintains Overweight on Zoetis, Lowers Price Target to $230
23 Apr 24
Jack Daniels Parent Company, EA, Cognizant Among 6 Stocks That Shine When Nvidia Slips: Analysis
19 Apr 24
Scout Clean Energy Announces 12-Year Virtual Power Purchase Agreement With Zoetis Inc.
18 Apr 24
Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years
16 Apr 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
24 Apr 24
Bragar Eagel & Squire, P.C. Is Investigating Zoetis, and Morgan Stanley and Encourages Investors to Contact the Firm
23 Apr 24
ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation – ZTS
23 Apr 24
Zoetis (ZTS) Drops on Report that Arthritis Drugs May Sicken Pets – Hagens Berman
22 Apr 24
SHAREHOLDER ALERT: Zoetis Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
19 Apr 24